Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Immunotherapy

Merck Reports Q1 Loss From Cidara Charge as Sales Beat and 2026 Outlook Rises

A one-time deal cost turned a strong sales quarter into a loss.

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

Securities Class Action Filed Against ImmunityBio After FDA Flags Anktiva Marketing

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

MoonLake Investors Get Deadline Reminder as Securities Suits Mount Over Sonelokimab Trial

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC